Vnitřní lékařství 5/2021

HLAVNÍ TÉMA Osteoporóza u premenopauzálnych žien 290 | VNITŘNÍ LÉKAŘSTVÍ / Vnitř Lék 2021; 67(5): 284–290 / www.casopisvnitrnilekarstvi.cz 8. Dutta D et al. Occurrence & predictors of osteoporosis & impact of body composition alterations on bone mineral health in asymptomatic pre-menopausal women with HIV infection. The Indian journal of medical research, 2018; 147(5): p. 484–495. 9. Cairoli E et al. Bone involvement in young adults with cystic fibrosis awaiting lung transplantation for end-stage respiratory failure. Osteoporos Int, 2019. 30(6): p. 1255–1263. 10. Martínez-Morillo MD. Grados, and S. Holgado, Premenopausal Osteoporosis: How to Treat? Reumatología Clínica (English Edition), 2012; 8(2): p. 93–97. 11. Weaver CM et al. The National Osteoporosis Foundation’s position statement on peak bone mass development and lifestyle factors: a systematic review and implementation recommendations. Osteoporos Int, 2016; 27(4): p. 1281–1386. 12. Schousboe JT et al. Executive summary of the 2013 International Society for Clinical Densitometry Position Development Conference on bone densitometry. J Clin Densi- tom, 2013; 16(4): p. 455–466. 13. Shepherd JA et al. Executive Summary of the 2015 ISCD Position Development Con- ference on Advanced Measures From DXA and QCT: Fracture Prediction Beyond BMD. J Clin Densitom, 2015; 18(3): p. 274–286. 14. Greendale GA et al. Bone mineral density loss in relation to the final menstrual period in a multiethnic cohort: results from the Study of Women’s Health Across the Nation (SWAN). J Bone Miner Res, 2012; 27(1): p. 111–118. 15. Ferrari S et al. Osteoporosis in young adults: pathophysiology, diagnosis, and manage- ment. Osteoporos Int, 2012; 23(12): p. 2735–2748. 16. Lewiecki EM et al. Proceedings of the 2016 Santa Fe Bone Symposium: New Concepts in the Management of Osteoporosis and Metabolic Bone Diseases. Journal of Clinical Den- sitometry, 2017; 20(2): p. 134–152. 17. Lewiecki EM et al. International Society for Clinical Densitometry 2007 Adult and Pe- diatric Official Positions. Bone, 2008; 43(6): p. 1115–1121. 18. Buckley L et al. 2017 American College of Rheumatology Guideline for the Preven- tion and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol, 2017; 69(8): p. 1521–1537. 19. Ferrari SL et al. Childhood fractures are associated with decreased bone mass gain during puberty: an early marker of persistent bone fragility? J Bone Miner Res, 2006; 21(4): p. 501–507. 20. Greendale GA et al. Premenopausal and early postmenopausal trabecular bone score (TBS) and fracture risk: Study of Women’s Health Across the Nation (SWAN). Bone, 2020; 140: p. 115543. 21. Kužma M et al. High Serum Fractalkine is Associated with Lower Trabecular Bone Score in Premenopausal Women with Graves’ Disease. HormMetab Res, 2018; 50(8): p. 609–614. 22. Jackuliak P et al. Good long-term glycemic compensation is associated with better trabecular bone score in postmenopausal women with type 2 diabetes. Physiol Res, 2019; 68(Suppl 2): p. S149–s156. 23. Ross AC et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol M et al. Effects of the bisphosphonate, alendronate, on parturition in the rat. Toxicol Appl Phar- macol, 1993; 121(2): p. 217–223. 25. Sokal A et al. Pregnancy and newborn outcomes after exposure to bisphosphonates: a case-control study. Osteoporos Int, 2019; 30(1): p. 221–229. 26. Cohen A, Shane E. Evaluation and management of the premenopausal woman with low BMD. Current osteoporosis reports, 2013; 11(4): p. 276–285. 27. Fink HA et al. Long-Term Drug Therapy and Drug Discontinuations and Holidays for Osteoporosis Fracture Prevention: A Systematic Review. Ann Intern Med, 2019; 171(1): p. 37–50. 28. Wotton CJ et al. Use of oral bisphosphonates and risk of hospital admission with osteo- necrosis of the jaw: Large prospective cohort study in UK women. Bone, 2019. 124: p. 69–74. 29. Wood J et al. Novel antiangiogenic effects of the bisphosphonate compound zoledro- nic acid. J Pharmacol Exp Ther, 2002; 302(3): p. 1055–1061. 30. Taxel P et al. Cancer Treatment-Induced Bone Loss in Women With Breast Cancer and Men With Prostate Cancer. Journal of the Endocrine Society, 2018; 2(7): p. 574–588. 31. Gnant M et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal wo- men with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol, 2011; 12(7): p. 631–641. 32. Hershman DL et al. Prevention of bone loss by zoledronic acid in premenopausal wo- men undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment. J Clin Endocrinol Metab, 2010; 95(2): p. 559–566. 33. Delmas PD et al. Bisphosphonate risedronate prevents bone loss in women with arti- ficial menopause due to chemotherapy of breast cancer: a double-blind, placebo-cont- rolled study. J Clin Oncol, 1997; 15(3): p. 955–962. 34. Hines SL et al. Phase III randomized, placebo-controlled, double-blind trial of risedro- nate for the prevention of bone loss in premenopausal women undergoing chemothe- rapy for primary breast cancer. J Clin Oncol, 2009; 27(7): p. 1047–1053. 35. Bone HG et al. Effects of Denosumab on Bone Mineral Density and Bone Turnover in Postmenopausal Women. The Journal of Clinical Endocrinology & Metabolism, 2008; 93(6): p. 2149–2157. 36. Finkelstein JS et al. Prevention of estrogen deficiency-related bone loss with human pa- rathyroid hormone-(1-34): a randomized controlled trial. Jama, 1998; 280(12): p. 1067–1073. 37. Cohen A et al. Teriparatide for idiopathic osteoporosis in premenopausal women: a pi- lot study. J Clin Endocrinol Metab, 2013; 98(5): p. 1971–1981. 38. Choe EY et al. Effect of teriparatide on pregnancy and lactation-associated osteo- porosis with multiple vertebral fractures. J Bone Miner Metab, 2012; 30(5): p. 596–601. 39. Langdahl BL et al. Teriparatide versus alendronate for treating glucocorticoid-indu- ced osteoporosis: an analysis by gender and menopausal status. Osteoporos Int, 2009; 20(12): p. 2095–2104. 40. Curtis JR et al. Population-based assessment of adverse events associated with long- -term glucocorticoid use. Arthritis Rheum, 2006; 55(3): p. 420–426. 41. Rizzoli R, Biver E. Glucocorticoid-induced osteoporosis: who to treat with what agent? Nat Rev Rheumatol, 2015; 11(2): p. 98–109. 42. Payer J, Brazdilova K, Jackuliak P. Management of glucocorticoid-induced osteoporosis: prevalence, and emerging treatment options. Drug Healthc Patient Saf, 2010; 2: p. 49–59. 43. Van Staa TP et al. Use of oral corticosteroids and risk of fractures. J Bone Miner Res, 2000; 15(6): p. 993–1000. 44. Miller KK et al. Determinants of skeletal loss and recovery in anorexia nervosa. J Clin Endocrinol Metab, 2006; 91(8): p. 2931–2937. 45. Tichá Ľ et al. Porucha kostného metabolizmu pri mentálnej anorexii Čes-slov Pediat., 2016; 71(5–6): p. 287–292. 46. Sim LA et al. Effect on bone health of estrogen preparations in premenopausal wo- men with anorexia nervosa: a systematic review and meta-analyses. Int J Eat Disord, 2010; 43(3): p. 218–225. 47. Baqi L et al. Thyrotropin versus thyroid hormone in regulating bone density and tur- nover in premenopausal women. Endocr Regul, 2010; 44(2): p. 57–63. 48. Kuzma M, Payer J. (Growth hormone deficiency, its influence on bone mineral density and risk of osteoporotic fractures). Cas Lek Cesk, 2010; 149(5): p. 211–216. 49. Kužma M et al. (Issues related to secondary osteoporosis associated with growth hor- mone deficiency in adulthood). Vnitr Lek, 2017; 63(10): p. 658–661. 50. Kužma M et al. Impact of the growth hormone replacement on bone status in growth hormone deficient adults. Growth Horm IGF Res, 2014; 24(1): p. 22–28. 51. Kužma M et al. Kvalita kosti u akromegalikov. Vnitřní lékařství, 2017; 63(9): p. 589–592. 52. Kužma M et al. Trabecular Bone Score Change Differs with Regard to 25(OH)D Le- vels in Patients Treated for Adult-Onset Growth Hormone Deficiency. Endocrine Practi- ce, 2016; 22(8): p. 951–958. 53. Kužma M et al. Non-invasive DXA-derived bone structure assessment of acromegaly patients: a cross-sectional study. Eur J Endocrinol, 2019; 180(3): p. 201–211. 54. World Health, O., Guideline: calcium supplementation in pregnant women. 2013, Ge- neva: World Health Organization. 55. Holick MF et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endo- crine Society clinical practice guideline. J Clin Endocrinol Metab, 2011; 96(7): p. 1911–1930. 56. Kalkwarf HJ et al. The effect of calcium supplementation on bone density during lacta- tion and after weaning. N Engl J Med, 1997; 337(8): p. 523–528. 57. Scioscia MF et al. Severe Bone Microarchitecture Impairment in Women With Pregnan- cy and Lactation-Associated Osteoporosis. J Endocr Soc, 2021; 5(5): p. bvab031. 58. O’Sullivan SM et al. Bisphosphonates in pregnancy and lactation-associated osteopo- rosis. Osteoporos Int, 2006; 17(7): p. 1008–1012. 59. Cerit ET, Cerit M. A case of pregnancy and lactation associated osteoporosis in the third pregnancy; robust response to teriparatide despite delayed administration. Bone reports, 2020; 13: p. 100706–100706. 60. Recker RR et al. Bone gain in young adult women. Jama, 1992; 268(17): p. 2403–2408. 61. Peris P et al. Bone mineral density evolution in young premenopausal women with idiopathic osteoporosis. Clin Rheumatol, 2007; 26(6): p. 958–961.